Multiple Myeloma

An overview of how earlier use of CAR T-cell therapy is reshaping multiple myeloma treatment and what pharmacists should know about toxicity management, supportive care, and evolving clinical practice.

Phase 3 MagnetisMM-5 trial data demonstrated that Elrexfio (elranatamab) significantly improved progression-free survival compared with standard-of-care therapy in patients with relapsed or refractory multiple myeloma.

FDA fast track designation advances oral EP300/CBP inhibitor OPN-6602 for relapsed/refractory multiple myeloma, highlighting novel hematology-oncology options and key pharmacist considerations.

Phase 3 trial data show that isatuximab quadruplet improves MRD negativity in transplant-eligible patients with multiple myeloma.

Team-based, multidisciplinary care aids personalized treatment, improving coordination across complex therapies, and enhances patient outcomes and long-term quality of life.

Insights from the 2026 HOPA Annual Conference highlight the pharmacist's role in operationalizing belantamab mafodotin.

Real-world data show racial gaps in multiple myeloma CAR T-cell therapy; pharmacists in oncology can boost referrals, equity, and access.

Data from a phase 2 response-adapted trial identify CD38 expression, plasma cell phenotype, and immune microenvironment as critical determinants of single-agent daratumumab efficacy.

Evolving myeloma therapies and pharmacist-led care reshape outcomes, tackling resistance, toxicity, and personalized treatment sequencing.

Circulating tumor cells detected in peripheral blood may serve as a powerful prognostic biomarker in newly diagnosed multiple myeloma.

FDA approval expands the use of teclistamab plus daratumumab, which significantly improved survival in the MajesTEC-3 trial.

Carfilzomib may boost BCMA CAR T-cell therapy after relapse in multiple myeloma, guiding oncology pharmacists on safer immunotherapy sequencing.

Linvoseltamab joins 3 other bispecific T-cell–engaging antibodies in multiple myeloma, offering deep and durable responses in heavily pretreated patients.

Oncology pharmacists discuss the transformative role of bispecific antibodies in treating relapsed/refractory multiple myeloma, addressing challenges and patient care strategies.

FDA accepts Iberdomide new drug application for relapsed or refractory multiple myeloma; pharmacists prepare for oral anti-CD38 combos, MRD-driven care.

Innovent’s trispecific antibody IBI3003 has received FDA fast track designation for R/R MM, supported by early clinical data showing strong efficacy and manageable safety in heavily pretreated and high-risk patients.

Phase 1 data show oral NSD2 inhibitor KTX-1001 delivers durable disease control in high-risk myeloma, with manageable thrombocytopenia and combo plans.

FDA approves a new quadruplet therapy for newly diagnosed multiple myeloma, enhancing treatment options for patients ineligible for stem cell transplant.

FDA's draft guidance on MRD and CR as end points accelerates multiple myeloma therapy approvals, enhancing patient access and transforming oncology practices.

Innovative immunotherapy strategies, like linvoseltamab, show promise in treating multiple myeloma, potentially reducing reliance on traditional transplants.

Teclistamab-cqyv shows promising results in treating refractory multiple myeloma, significantly improving survival rates and offering new hope for patients.

New research uncovers why multiple myeloma affects men more than women, highlighting sex-based differences in disease presentation and risk factors.

A new dual-antibody therapy shows promise in treating extramedullary multiple myeloma, offering hope for patients with limited options.

Pharmacists can play a pivotal role in overcoming the many challenges that exist in accessing immunomodulatory drugs in multiple myeloma.

A high-fiber, plant-based diet shows promise in delaying multiple myeloma progression and enhancing metabolism and immune response in patients with precursor conditions.